MDXG - MiMedx Group, Inc. Stock Price, Fair Value and News

6.26USD+0.01 (+0.16%)Market Closed

Market Summary

USD6.26+0.01

Market Closed

0.16%

MDXG Stock Price

View Fullscreen

MDXG RSI Chart

MDXG Valuation

Market Cap

920.0M

Price/Earnings (Trailing)

15.8

Price/Sales (Trailing)

2.86

EV/EBITDA

33.01

Price/Free Cashflow

37.11

MDXG Price/Sales (Trailing)

MDXG Profitability

EBT Margin

9.53%

Return on Equity

40.8%

Return on Assets

24.36%

Free Cashflow Yield

2.69%

MDXG Fundamentals

MDXG Revenue

Revenue (TTM)

321.5M

Rev. Growth (Yr)

16.75%

Rev. Growth (Qtr)

6.27%

MDXG Earnings

Earnings (TTM)

58.2M

Earnings Growth (Yr)

13.0K%

Earnings Growth (Qtr)

526.63%

Breaking Down MDXG Revenue

Last 7 days

-0.5%

Last 30 days

-17.7%

Last 90 days

-22.1%

Trailing 12 Months

71.5%

How does MDXG drawdown profile look like?

MDXG Financial Health

Current Ratio

3.57

Debt/Equity

0.34

Debt/Cashflow

0.56

MDXG Investor Care

Shares Dilution (1Y)

28.82%

Diluted EPS (TTM)

0.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	280.6M	295.0M	309.0M	321.5M
2022	240.9M	239.7M	244.3M	267.8M
2021	246.5M	261.0M	259.8M	242.0M
2020	294.4M	280.6M	256.1M	248.2M
2019	341.5M	313.5M	315.4M	299.3M
2018	336.5M	351.4M	354.4M	359.1M
2017	260.4M	283.6M	303.2M	321.1M
2016	199.9M	211.6M	227.0M	245.0M
2015	139.4M	159.5M	175.0M	187.3M
2014	67.2M	79.2M	96.6M	118.2M
2013	34.9M	43.5M	51.7M	59.2M
2012	10.4M	13.4M	19.2M	27.1M
2011	2.5M	4.3M	6.0M	7.8M
2010	0	0	0	788.9K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of MiMedx Group, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 23, 2024	hulse william frank iv	sold (taxes)	-57,913	6.51	-8,896	general counsel and cao
Apr 08, 2024	hulse william frank iv	sold (taxes)	-61,382	6.9	-8,896	general counsel and cao
Mar 13, 2024	hulse william frank iv	sold	-162,029	7.95	-20,381	general counsel and cao
Mar 04, 2024	hulse william frank iv	sold (taxes)	-126,799	8.26	-15,351	general counsel and cao
Mar 01, 2024	doug rice	acquired	-	-	58,478	chief financial officer
Mar 01, 2024	hulse william frank iv	acquired	-	-	59,127	general counsel and cao
Mar 01, 2024	whitlow ricci s	acquired	-	-	58,478	chief operating officer
Feb 20, 2024	whitlow ricci s	sold	-122,351	8.012	-15,271	chief operating officer
Feb 16, 2024	whitlow ricci s	sold	-125,075	8.073	-15,493	chief operating officer
Feb 15, 2024	whitlow ricci s	sold	-122,496	8.06	-15,198	chief operating officer

Which funds bought or sold MDXG recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	added	11.83	-4,782	258,897	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	34,000	34,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-6.72	-636,847	2,881,620	-%
Apr 25, 2024	Lindbrook Capital, LLC	added	0.66	-928	7,061	-%
Apr 24, 2024	Spire Wealth Management	unchanged	-	-1,760	30,800	-%
Apr 24, 2024	Robeco Institutional Asset Management B.V.	sold off	-100	-96,374	-	-%
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	-6,000	39,000	-%
Apr 24, 2024	BROWN ADVISORY INC	unchanged	-	-57,780	415,800	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.45	-58,000	29,000	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-2,280	46,200	-%

Are Funds Buying or Selling MDXG?

Are funds buying MDXG calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MDXG

No. of Funds

Unveiling MiMedx Group, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.64%	6,567,254	SC 13G/A
Jan 25, 2024	blackrock inc.	8.2%	9,533,518	SC 13G/A
Dec 27, 2023	falcon fund 2 holding company, l.p.	19.3%	28,195,249	SC 13D/A
Feb 09, 2023	vanguard group inc	5.36%	6,094,595	SC 13G
Feb 01, 2023	blackrock inc.	6.8%	7,781,521	SC 13G/A
Jun 15, 2022	prescience investment group llc	5.0%	5,719,888	SC 13G
May 09, 2022	prescience investment group llc	5.0%	5,719,888	SC 13D/A
Apr 28, 2022	prescience investment group llc	5.0%	5,719,888	SC 13D
Feb 08, 2022	prescience investment group llc	5.5%	6,119,888	SC 13G/A
Feb 04, 2022	blackrock inc.	6.5%	7,276,373	SC 13G

Recent SEC filings of MiMedx Group, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	4	Insider Trading
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 10, 2024	4	Insider Trading
Mar 27, 2024	8-K	Current Report
Mar 18, 2024	3	Insider Trading
Mar 18, 2024	3	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to MiMedx Group, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

MiMedx Group, Inc. News

Latest updates

MiMedx Group, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	6.3%	86,832,000	81,712,000	81,257,000	71,676,000	74,375,000	67,689,000	66,883,000	58,894,000	50,813,000	63,074,000	68,165,000	59,967,000	68,548,000	64,303,000	53,647,000	61,736,000	76,400,000	88,863,000	67,437,000	66,555,000	92,586,000
Gross Profit	9.1%	72,990,000	66,922,000	67,674,000	59,257,000	60,006,000	55,501,000	55,060,000	48,958,000	43,715,000	52,945,000	55,405,000	50,326,000	57,730,000	54,014,000	45,449,000	51,711,000	63,691,000	75,658,000	57,688,000	59,137,000	82,183,000
S&GA Expenses	3.4%	54,350,000	52,571,000	51,925,000	52,279,000	49,835,000	53,475,000	55,793,000	49,570,000	49,554,500	46,289,000	53,599,000	45,404,000	48,705,500	48,046,000	37,329,000	46,942,000	45,444,000	51,258,000	50,641,000	50,862,000	66,295,500
R&D Expenses	-273.3%	-5,503,000	3,175,000	8,497,000	6,496,000	-4,728,000	5,953,000	5,512,000	5,964,000	-2,838,000	4,368,000	4,063,000	4,339,000	3,434,000	3,372,000	2,259,000	2,650,000	2,719,000	2,691,000	2,828,000	2,902,000	4,539,500
EBITDA Margin	120.3%	0.08	0.04	-0.05	-0.10	-0.12	-0.11	-0.09	-0.05	-0.04	-0.12	-0.18	-0.22	-	-	-	-	-	-	-	-	-
Interest Expenses	5.1%	-1,593,500	-1,680,000	-1,630,000	-1,553,000	-1,450,000	-1,270,000	-1,170,000	-1,126,000	-1,174,000	-963,000	-1,371,000	-1,472,000	-1,508,000	-1,472,000	-2,574,000	-2,387,000	-2,395,000	-2,255,000	-269,000	211,000	-
Income Taxes	-6423.9%	-37,374,500	591,000	-74,000	51,000	28,000	53,000	62,000	63,000	-107,500	301,000	-5,000	58,000	-1,020,000	38,000	27,000	-11,304,000	220,000	-309,000	42,000	42,000	27,497,000
Earnings Before Taxes	177.4%	25,313,500	9,125,000	1,126,000	-4,932,000	9,858,000	-8,373,000	-10,806,000	-10,426,000	91,500	-2,038,000	-1,784,000	-8,324,000	-17,600,000	-19,379,000	-8,439,000	-16,125,000	-7,256,000	12,070,000	-17,168,000	-13,231,000	-8,727,000
EBT Margin	94.0%	0.10	0.05	-0.04	-0.09	-0.11	-0.11	-0.08	-0.05	-0.04	-0.11	-0.18	-0.22	-	-	-	-	-	-	-	-	-
Net Income	526.6%	53,477,000	8,534,000	1,200,000	-4,983,000	-414,000	-8,426,000	-10,868,000	-10,489,000	2,215,000	-2,339,000	-1,779,000	-8,382,000	-16,580,000	-19,417,000	-8,466,000	-4,821,000	-7,476,000	12,379,000	-17,210,000	-13,273,000	-36,224,000
Net Income Margin	1190.5%	0.18	0.01	-0.04	-0.09	-0.11	-0.11	-0.08	-0.05	-0.04	-0.11	-0.18	-0.21	-	-	-	-	-	-	-	-	-
Free Cashflow	-19.2%	9,830,000	12,163,000	7,476,000	-4,681,000	-6,291,000	610,000	-3,385,000	-10,341,000	-3,557,000	5,783,000	1,194,000	-8,620,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	26.5%	239	189	176	168	171	173	169	174	188	181	187	191	202	213	151	159	167	179	170	107	123
Current Assets	6.3%	164	155	141	132	134	136	131	136	149	142	148	150	161	171	108	116	123	134	123	57.00	74.00
Cash Equivalents	1.0%	82.00	81.00	69.00	61.00	66.00	73.00	73.00	76.00	87.00	91.00	85.00	85.00	96.00	110	48.00	54.00	69.00	94.00	97.00	28.00	45.00
Inventory	10.2%	21.00	19.00	17.00	15.00	13.00	14.00	13.00	13.00	11.00	11.00	10.00	12.00	10.00	11.00	11.00	9.00	9.00	12.00	15.00	16.00	16.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	11.00	11.00	10.00	11.00	12.00	12.00	13.00	15.00	16.00	17.00
Goodwill	0%	19.00	19.00	19.00	20.00	19.00	20.00	20.00	20.00	19.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00
Liabilities	1.2%	96.00	95.00	97.00	94.00	97.00	100	90.00	89.00	95.00	94.00	102	107	111	109	128	129	133	140	146	69.00	73.00
Current Liabilities	5.5%	46.00	44.00	44.00	41.00	44.00	46.00	37.00	37.00	42.00	42.00	51.00	55.00	59.00	57.00	64.00	64.00	67.00	73.00	78.00	64.00	72.00
Long Term Debt	-1.8%	48.00	49.00	49.00	49.00	49.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	61.00	62.00	62.00	62.00	63.00	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00	4.00	4.00	4.00	4.00	-	-
LT Debt, Non Current	-1.8%	48.00	49.00	49.00	49.00	49.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	61.00	62.00	62.00	62.00	63.00	-	-
Shareholder's Equity	10630.6%	143	1.00	-	-	-17.99	-	-	-	0.00	-	-	-	-0.15	13.00	23.00	30.00	34.00	40.00	25.00	38.00	50.00
Retained Earnings	28.6%	-133	-187	-195	-196	-191	-191	-183	-172	-161	-163	-161	-159	-151	-134	-115	-106	-102	-94.66	-107	-89.83	-76.56
Additional Paid-In Capital	46.7%	276	188	183	179	174	172	169	165	166	162	159	157	159	158	152	150	147	144	136	166	165
Shares Outstanding	25.7%	146	116	116	115	114	113	112	112	110	110	110	109	-	-	-	-	-	-	-	-	-
Float	-	-	-	760	-	-	-	388	-	-	-	1,381	-	-	-	538	-	-	-	425	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-19.8%	10,257	12,791	7,775	-4,048	-5,624	959	-3,005	-10,223	-3,232	6,330	1,599	-6,679	-10,267	-4,618	-3,097	-12,281	-23,122	-3,160	2,130	-15,260	1,534
Share Based Compensation	-5.1%	4,166	4,388	4,060	4,345	530	2,372	4,428	3,998	3,041	3,811	4,060	3,244	3,905	3,669	4,434	3,349	2,865	2,686	3,499	3,014	1,457
Cashflow From Investing	25.9%	-481	-649	-348	-677	-1,709	-374	-429	-148	-314	-580	-422	-2,079	-2,273	-710	-486	-1,086	-793	2,060	-330	-433	-1,186
Cashflow From Financing	-2516.2%	-8,940	370	4.00	-4.00	66.00	130	260	-1,036	22.00	-150	-916	-2,308	-1,243	66,734	-1,753	-2,177	-1,138	-1,707	66,748	-1,044	-285
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

MDXG Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net sales	$ 321,477,000	$ 267,841,000	$ 242,019,000
Cost of sales	54,634,000	48,316,000	39,628,000
Gross profit	266,843,000	219,525,000	202,391,000
Operating expenses:
Selling, general and administrative	211,124,000	208,673,000	194,846,000
Research and development	12,665,000	12,701,000	9,932,000
Investigation, restatement and related	5,176,000	12,177,000	3,791,000
Amortization of intangible assets	762,000	701,000	820,000
Impairment of intangible assets	0	0	53,000
Operating income (loss)	37,116,000	(14,727,000)	(7,051,000)
Other expense, net
Interest expense, net	(6,457,000)	(5,016,000)	(4,980,000)
Other expense, net	(26,000)	(4,000)	(23,000)
Income (loss) from continuing operations before income tax provision	30,633,000	(19,747,000)	(12,054,000)
Income tax provision benefit (expense) from continuing operations	36,806,000	(206,000)	(247,000)
Net income (loss) from continuing operations	67,439,000	(19,953,000)	(12,301,000)
Net (loss) income from discontinued operations	(9,211,000)	(10,244,000)	2,016,000
Net income (loss)	58,228,000	(30,197,000)	(10,285,000)
Net income (loss) from continuing operations available to common stockholders (Note 10)	$ 55,796,000	$ (26,533,000)	$ (18,437,000)
Basic net income (loss) per common share:
Discontinued operations - basic (in dollars per share)	$ (0.08)	$ (0.09)	$ 0.02
Basic net income (loss) per common share (in dollars per share)	0.40	(0.33)	(0.15)
Diluted net income (loss) per common share:
Continuing operations - basic (in dollars per share)	0.48	(0.24)	(0.17)
Continuing operations (in dollars per share)	0.43	(0.24)	(0.17)
Discontinued operations (in dollars per share)	(0.06)	(0.09)	0.02
Diluted net income (loss) per common share (in dollars per share)	$ 0.37	$ (0.33)	$ (0.15)
Weighted average shares outstanding - basic (in shares)	116,495,810	112,909,266	110,353,406
Weighted average shares outstanding - diluted (in shares)	145,962,462	112,909,266	110,353,406

MDXG Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 82,000	$ 65,950
Accounts receivable, net	53,871	43,084
Inventory	21,021	13,183
Prepaid expenses	5,624	7,315
Current assets of discontinued operations	0	1,331
Other current assets	1,745	3,335
Total current assets	164,261	134,198
Property and equipment, net	6,974	7,856
Right of use assets	2,132	3,400
Deferred tax assets	40,777	0
Goodwill	19,441	19,441
Intangible assets, net	5,257	5,852
Other assets	205	148
Noncurrent assets of discontinued operations	0	535
Total assets	239,047	171,430
Current liabilities:
Accounts payable	9,048	8,454
Accrued compensation	22,353	20,856
Accrued expenses	9,361	10,934
Current liabilities of discontinued operations	1,352	1,479
Other current liabilities	3,894	1,834
Total current liabilities	46,008	43,557
Long term debt, net	48,099	48,594
Other liabilities	2,223	4,773
Total liabilities	96,330	96,924
Commitments and contingencies (Note 16)
Convertible preferred stock Series B; $.001 par value; 100,000 shares authorized, 0 shares issued and outstanding at December 31, 2023 and 100,000 shares issued and outstanding at December 31, 2022	0	92,494
Stockholders’ equity (deficit)
Common stock; $.001 par value; 250,000,000 shares authorized, 146,227,639 issued and outstanding at December 31, 2023 and 187,500,000 authorized, 113,705,447 issued and outstanding at December 31, 2022	146	114
Additional paid-in capital	276,249	173,804
Accumulated deficit	(133,678)	(191,906)
Total stockholders’ equity (deficit)	142,717	(17,988)
Total liabilities, convertible preferred stock, and stockholders’ equity (deficit)	$ 239,047	$ 171,430

About MiMedx Group, Inc.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

CEO	Mr. Joseph H. Capper
WEBSITE	mimedx.com
INDUSTRY	Biotechnology
EMPLOYEES	867

MiMedx Group, Inc. Frequently Asked Questions

What is the ticker symbol for MiMedx Group, Inc.? What does MDXG stand for in stocks?

MDXG is the stock ticker symbol of MiMedx Group, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MiMedx Group, Inc. (MDXG)?

As of Fri Apr 26 2024, market cap of MiMedx Group, Inc. is 919.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDXG stock?

You can check MDXG's fair value in chart for subscribers.

What is the fair value of MDXG stock?

You can check MDXG's fair value in chart for subscribers. The fair value of MiMedx Group, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MiMedx Group, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MDXG so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MiMedx Group, Inc. a good stock to buy?

The fair value guage provides a quick view whether MDXG is over valued or under valued. Whether MiMedx Group, Inc. is cheap or expensive depends on the assumptions which impact MiMedx Group, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDXG.

What is MiMedx Group, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, MDXG's PE ratio (Price to Earnings) is 15.8 and Price to Sales (PS) ratio is 2.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDXG PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MiMedx Group, Inc.'s stock?

In the past 10 years, MiMedx Group, Inc. has provided 0.009 (multiply by 100 for percentage) rate of return.